| Active ingredient (INN) | Insulin glargine |
|---|---|
| Brand names | Lantus, Toujeo, Semglee, Basaglar |
| ATC level 5 | A10AE04 |
| ATC level 4 | A10AE |
| Drug class | Long-acting insulin analogue |
| Therapeutic category | Endocrine/Metabolic |
| Strength | 100 units/ml · 300 units/ml |
| Dosage form | solution for injection |
| Route of administration | subcutaneous |
| WHO Essential Medicine | Yes (2023) |
| Controlled substance | No |
| Marketing-authorisation holders | Eli Lilly Australia Pty Ltd, Sanofi-Aventis Australia Pty Ltd, Winthrop U.S., Sanofi-Aventis U.S. LLC |
| Registrations on file | 11 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| BASAGLAR insulin glargine | 100 IU | injsol | 🇦🇺 AU | Eli Lilly Australia Pty Ltd | Active |
| BASAGLAR KwikPen insulin glargine | 100 IU | injsol | 🇦🇺 AU | Eli Lilly Australia Pty Ltd | Active |
| Optisulin | 100IU | — | 🇦🇺 AU | Sanofi-Aventis Australia Pty Ltd | Active |
| Optisulin Solostar | 100IU | — | 🇦🇺 AU | Sanofi-Aventis Australia Pty Ltd | Active |
| TOUJEO SOLOSTAR insulin glargine | 300 units | — | 🇦🇺 AU | Sanofi-Aventis Australia Pty Ltd | Active |
| SEMGLEE insulin glargine | 100 IU | — | 🇦🇺 AU | — | Active |
| TOUJEO MAX SOLOSTAR insulin glargine | 300 units | — | 🇦🇺 AU | Sanofi-Aventis Australia Pty Ltd | Active |
| Insulin Glargine Solostar | 100[iU]/mL | injection | 🇺🇸 US | Winthrop U.S. | Discontinued |
| Insulin Glargine | 100[iU]/mL | injection | 🇺🇸 US | Winthrop U.S. | Discontinued |
| Insulin glargine U- | 300[iU]/mL | injection | 🇺🇸 US | Sanofi-Aventis U.S. LLC | Active |
| Insulin glargine U-300 | 300[iU]/mL | injection | 🇺🇸 US | Sanofi-Aventis U.S. LLC | Active |